**Market Applicability/Effective Date**

<table>
<thead>
<tr>
<th>Market</th>
<th>FL &amp; FHK</th>
<th>FL MMA</th>
<th>FL LTC</th>
<th>GA</th>
<th>KS</th>
<th>KY</th>
<th>LA</th>
<th>MD</th>
<th>NJ</th>
<th>NV</th>
<th>NY</th>
<th>TN</th>
<th>TX</th>
<th>WA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicable</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>X</td>
<td>NA</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

*FHK- Florida Healthy Kids

## Tasmar (tolcapone)

### Override(s) | Approval Duration
---|---
Prior Authorization | 1 year

### Medications | Quantity Limit
---|---
Tasmar (tolcapone) | N/A

**APPROVAL CRITERIA**

Requests for Tasmar (tolcapone) may be approved if the following criteria are met:

I. Individual is using for the symptomatic treatment of Parkinsonian syndrome; **AND**

II. Individual is using concomitantly with carbidopa/levodopa therapy; **AND**

III. Individual is not responding satisfactorily to, or is not an appropriate candidate for other adjunctive therapies.

**Note:** Tasmar (tolcapone) has a black box warning for the risk of potentially fatal, acute fulminant liver failure. Because of the risk of liver injury and because Tasmar, when it is effective, provides an observable symptomatic benefit, the individual who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from Tasmar. Tasmar therapy should not be initiated if the individual exhibits clinical evidence of liver disease or two serum glutamic-pyruvic transaminase/alanine aminotransferase (SGPT/ALT) or serum glutamic-oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST) values greater than the upper limit of normal. Individuals with severe dyskinesia...
or dystonia should be treated with caution and those who develop evidence of hepatocellular injury while on the medication and are withdrawn from the drug for any reason may be at increased risk for liver injury if the medication is reintroduced. Accordingly, such individuals should not ordinarily be considered for retreatment.

### Market Applicability/Effective Date

<table>
<thead>
<tr>
<th>Market</th>
<th>FL &amp; FHK</th>
<th>FL MMA</th>
<th>FL LTC</th>
<th>GA</th>
<th>KS</th>
<th>KY</th>
<th>LA</th>
<th>MD</th>
<th>NJ</th>
<th>NV</th>
<th>NY</th>
<th>TN</th>
<th>TX</th>
<th>WA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicable</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>X</td>
<td>NA</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

*FHK- Florida Healthy Kids

### Key References


DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2016; Updated periodically.